{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:31:31Z","timestamp":1793197891915,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jchf.2023.04.018","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T14:07:53Z","timestamp":1688393273000},"page":"735-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Cardiac Myosin Inhibitors for Managing\u00a0Obstructive Hypertrophic\u00a0Cardiomyopathy"],"prefix":"10.1016","volume":"11","author":[{"given":"John W.","family":"Ostrominski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry M.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn Y.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2023.04.018_bib1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary Artery Risk Development in (Young) Adults","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.04.018_bib2","first-page":"376","article-title":"Global burden of hypertrophic cardiomyopathy","volume":"6","author":"Maron","year":"2018","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2023.04.018_bib3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41569-022-00682-0","article-title":"Targeting the sarcomere in inherited cardiomyopathies","volume":"19","author":"Lehman","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib4","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/CIRCRESAHA.121.318346","article-title":"Molecular genetic basis of hypertrophic cardiomyopathy","volume":"128","author":"Marian","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jchf.2023.04.018_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41588-020-00764-0","article-title":"Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity","volume":"53","author":"Harper","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.jchf.2023.04.018_bib6","article-title":"Large scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy","author":"Tadros","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.jchf.2023.04.018_bib7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2023.04.018_bib8","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/eurheartj\/ehl041","article-title":"Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy","volume":"27","author":"Elliott","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2023.04.018_bib9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jacc.2009.01.079","article-title":"Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study","volume":"54","author":"Sorajja","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.jchf.2023.04.018_bib11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa1002659","article-title":"Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy","volume":"363","author":"Ho","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2023.04.018_bib12","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.jchf.2023.04.018_bib13","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib14","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of hypertrophic cardiomyopathy: JACC State-of-the-Art Review","volume":"79","author":"Maron","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2023.04.018_bib16","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2015.02.061","article-title":"Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies","volume":"65","author":"Maron","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.007673","article-title":"Guideline-based referral for septal reduction therapy in obstructive hypertrophic cardiomyopathy is associated with excellent clinical outcomes","volume":"12","author":"Kimmelstiel","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jchf.2023.04.018_bib18","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2005.02.090","article-title":"Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy","volume":"46","author":"Ommen","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib19","first-page":"245","article-title":"Alcohol septal ablation for obstructive hypertrophic cardiomyopathy","volume":"11","author":"Sorajja","year":"2022","journal-title":"Intervent Cardiol Clin"},{"key":"10.1016\/j.jchf.2023.04.018_bib20","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.athoracsur.2022.05.062","article-title":"Impact of hospital volume on outcomes of septal myectomy for hypertrophic cardiomyopathy","volume":"114","author":"Holst","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jchf.2023.04.018_bib21","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamacardio.2016.0252","article-title":"Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide Inpatient Database, 2003-2011","volume":"1","author":"Kim","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib22","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/j.amjmed.2017.12.031","article-title":"Clinical profile of nonresponders to surgical myectomy with obstructive cardiomyopathy","volume":"131","author":"Wells","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.jchf.2023.04.018_bib23","first-page":"896","article-title":"A\u00a0systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy","volume":"3","author":"Liebregts","year":"2015","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2023.04.018_bib24","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.04.018_bib25","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.119.044366","article-title":"Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the ShaRe Registry","volume":"141","author":"Marstrand","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.04.018_bib26","article-title":"Outcomes in patients with hypertrophic cardiomyopathy awaiting heart transplantation","volume":"11","author":"Cisneros","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.018_bib27","doi-asserted-by":"crossref","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jchf.2023.04.018_bib28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A\u00a0small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jchf.2023.04.018_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148557","article-title":"Myosin modulators: emerging approaches for the treatment of cardiomyopathies and heart failure","volume":"132","author":"Day","year":"2022","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jchf.2023.04.018_bib30","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jchf.2023.04.018_bib31","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib32","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2023.04.018_bib33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib35","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s40265-022-01739-7","article-title":"Mavacamten: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jchf.2023.04.018_bib36","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/gim.2016.90","article-title":"Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples","volume":"19","author":"Walsh","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.jchf.2023.04.018_bib37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1161\/CIRCRESAHA.110.223842","article-title":"Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor","volume":"111","author":"Moore","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.jchf.2023.04.018_bib38","doi-asserted-by":"crossref","first-page":"E7486","DOI":"10.1073\/pnas.1720342115","article-title":"Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin","volume":"115","author":"Rohde","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jchf.2023.04.018_bib39","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human \u03b2-cardiac myosin and mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jchf.2023.04.018_bib40","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.119.042339","article-title":"Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy","volume":"141","author":"Toepfer","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.04.018_bib41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev-genom-083118-015306","article-title":"Advances in the genetic basis and pathogenesis of sarcomere cardiomyopathies","volume":"20","author":"Yotti","year":"2019","journal-title":"Annu Rev Genom Hum Genet"},{"key":"10.1016\/j.jchf.2023.04.018_bib42","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A\u00a0small-molecular modulatory of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jchf.2023.04.018_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2021.167295","article-title":"Two classes of myosin inhibitors, para-nitroblebbistatin and mavacamten, stabilize \u03b2-cardiac myosin in different structural and functional states","volume":"433","author":"Gollapudi","year":"2021","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.jchf.2023.04.018_bib44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1113\/JP275050","article-title":"Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament","volume":"596","author":"Kampourakis","year":"2018","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib45","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","article-title":"In\u00a0vitro and in\u00a0vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jchf.2023.04.018_bib46","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2015.03.016","article-title":"Cardiovascular drug development: is it dead or just hibernating?","volume":"65","author":"Fordyce","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib47","article-title":"Cardiac myosin inhibitors as a novel treatment option for obstructive hypertrophic cardiomyopathy: addressing the core of the matter","volume":"11","author":"Masri","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2023.04.018_bib48","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1001\/jamacardio.2022.5099","article-title":"Effects of mavacamten on measures of cardiopulmonary exercise testing beyond peak oxygen consumption: a secondary analysis of the EXPLORER-HCM randomized trial","volume":"8","author":"Wheeler","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib49","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.04.018_bib50","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib51","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","article-title":"Dose-blinded myosin inhibition in patients with obstructive HCM referred for septal reduction therapy: outcomes through 32\u00a0weeks","volume":"147","author":"Desai","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.04.018_bib53","first-page":"369","article-title":"Mavacamten for hypertrophic cardiomyopathy: effectiveness and value","volume":"28","author":"Beinfeld","year":"2022","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.jchf.2023.04.018_bib54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2022.05.009","article-title":"Cardiac myosin inhibitors for obstructive hypertrophic cardiomyopathy: where are we on the hype cycle?","volume":"80","author":"Ommen","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib55","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Health status benefits of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy: results from the EXPLORER-HCM randomized clinical trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2023.04.018_bib56","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jacc.2015.06.1333","article-title":"Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction","volume":"66","author":"Maron","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib61","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijcard.2019.09.066","article-title":"Markers of responsiveness to disopyramide in patients with hypertrophic cardiomyopathy","volume":"297","author":"Habib","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib62","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ejhf.2737","article-title":"Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy","volume":"25","author":"Wheeler","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.018_bib63","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/jamacardio.2018.0789","article-title":"Long-term outcomes of pediatric-onset hypertrophic cardiomyopathy and age-specific risk factors for lethal arrhythmic events","volume":"3","author":"Maurizi","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib64","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/eurheartj\/ehab148","article-title":"Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy","volume":"42","author":"Marston","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2023.04.018_bib65","first-page":"143","article-title":"Hypertrophic cardiomyopathy in pregnancy","volume":"39","author":"Saberi","year":"2021","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.jchf.2023.04.018_bib66","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.01.023","article-title":"Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy","volume":"67","author":"Maron","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib67","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.jacc.2016.02.009","article-title":"Hypertrophic cardiomyopathy: job done or work in progress?","volume":"67","author":"Elliott","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib68","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijcard.2017.06.071","article-title":"Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"243","author":"Pelliccia","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib69","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002764","article-title":"Novel approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: the impact of late sodium current inhibition on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM) trial","volume":"9","author":"Olivotto","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.018_bib70","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","article-title":"Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial","volume":"3","author":"Axelsson","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jchf.2023.04.018_bib71","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/heartjnl-2015-308343","article-title":"Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial","volume":"102","author":"Axelsson","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2023.04.018_bib72","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","article-title":"Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study","volume":"11","author":"Olivotto","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.018_bib73","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.amjmed.2018.02.025","article-title":"Effect of spironolactone in myocardial fibrosis and other clinical variables in patients with hypertrophic cardiomyopathy","volume":"131","author":"Maron","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.jchf.2023.04.018_bib74","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamacardio.2018.4847","article-title":"Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy","volume":"4","author":"Coats","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib75","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s00059-022-05124-8","article-title":"The future of heart failure with preserved ejection fraction: deep phenotyping for targeted therapeutics","volume":"47","author":"Heinzel","year":"2022","journal-title":"Herz"},{"key":"10.1016\/j.jchf.2023.04.018_bib76","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/ejhf.2482","article-title":"Genetic and phenotypic profiling of supranormal ejection fraction reveals decreased survival and underdiagnosed heart failure","volume":"24","author":"Forrest","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.018_bib77","first-page":"583","article-title":"Supranormal left ventricular ejection fraction, stroke volume, and cardiovascular risk: findings from population-based cohort studies","volume":"10","author":"Shah","year":"2022","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2023.04.018_bib78","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/CIRCULATIONAHA.122.060199","article-title":"Disparities in cardiovascular mortality between Black and White adults in the United States, 1999-2019","volume":"146","author":"Kyalwazi","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2023.04.018_bib79","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0735-1097(02)02976-5","article-title":"Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy","volume":"41","author":"Maron","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib80","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1016\/j.jacc.2021.10.020","article-title":"Associations of race and ethnicity with presentation and outcomes of hypertrophic cardiomyopathy: JACC Focus Seminar 6\/9","volume":"78","author":"Ntusi","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib81","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009292","article-title":"Demographic and regional trends of hypertrophic cardiomyopathy-related mortality in the United States, 1999-2019","volume":"15","author":"Minhas","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2023.04.018_bib82","first-page":"1","article-title":"Cost and value in contemporary heart failure clinical guidance documents","volume":"10","author":"Ostrominski","year":"2022","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2023.04.018_bib83","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines","volume":"63","author":"Anderson","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib84","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib86","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamacardio.2021.0372","article-title":"Comparison of New York Heart Association class and patient-reported outcomes for heart failure with reduced ejection fraction","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2023.04.018_bib87","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jacc.2020.06.011","article-title":"Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers","volume":"76","author":"Lorenzini","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177923002366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177923002366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:03:39Z","timestamp":1761973419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177923002366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":81,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2213177923002366"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2023.04.018","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac Myosin Inhibitors for Managing\u00a0Obstructive Hypertrophic\u00a0Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2023.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}